Media stories about Mesoblast (NASDAQ:MESO) have trended positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mesoblast earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5118816538401 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Mesoblast Limited (MESO) Stock Formed Bearish Multiple Bottom. What To Expect? (nmsuherald.com)
- Global Stem Cells Market Size 2018 – EMD Millipore, SanBio, Mesoblast and MEDIPOST (opinioninvestor.com)
- Mesoblast (MESO) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB) (finance.yahoo.com)
- Mesoblast completes enrollment for chronic low back pain cell therapy trial: 4 things to know (beckersspine.com)
Several analysts have recently commented on MESO shares. Maxim Group set a $14.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research report on Thursday, March 29th. Cantor Fitzgerald set a $20.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Saturday, January 13th. Finally, Oppenheimer set a $16.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research report on Wednesday, December 20th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $13.54.
Mesoblast (NASDAQ:MESO) last announced its earnings results on Tuesday, February 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.09. Mesoblast had a negative net margin of 188.83% and a negative return on equity of 9.78%. The firm had revenue of $13.40 million for the quarter, compared to analyst estimates of $0.34 million. analysts forecast that Mesoblast will post -0.49 EPS for the current year.
Mesoblast Company Profile
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.